Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth A Jones

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Critical Criminology|January 1, 2026
Finding Ramón: Navigating Failure and Luck in MexicoGareth A Jones
The British Journal of Sociology|December 18, 2014
Where's the capital? A geographical essayGareth A Jones
BMC Neuroscience|May 1, 2012
Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortexSylvain Gigout, Gareth A Jones, Stephan Wierschke, et al.
Neuropharmacology|March 9, 2010
N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptorDavid R Thomas, Adeshola Dada, Gareth A Jones, et al.
The International Journal of Neuropsychopharmacology|August 31, 2012
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunctionPradeep J Nathan, Jeannette Watson, Jesper Lund, et al.
European Journal of Pharmacology|November 3, 2009
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristicsLee A Dawson, Christopher J Langmead, Adeshola Dada, et al.
Brain Research|April 17, 2007
Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophreniaMelanie J Robbins, Kathryn R Starr, Andy Honey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 31, 2007
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophreniaLee A Dawson, Katherine J Cato, Claire Scott, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Critical Criminology|January 1, 2026
Finding Ramón: Navigating Failure and Luck in MexicoGareth A Jones
The British Journal of Sociology|December 18, 2014
Where's the capital? A geographical essayGareth A Jones
BMC Neuroscience|May 1, 2012
Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortexSylvain Gigout, Gareth A Jones, Stephan Wierschke, et al.
Neuropharmacology|March 9, 2010
N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptorDavid R Thomas, Adeshola Dada, Gareth A Jones, et al.
The International Journal of Neuropsychopharmacology|August 31, 2012
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunctionPradeep J Nathan, Jeannette Watson, Jesper Lund, et al.
European Journal of Pharmacology|November 3, 2009
In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristicsLee A Dawson, Christopher J Langmead, Adeshola Dada, et al.
Brain Research|April 17, 2007
Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophreniaMelanie J Robbins, Kathryn R Starr, Andy Honey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 31, 2007
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophreniaLee A Dawson, Katherine J Cato, Claire Scott, et al.
Pageof 1